Candel Therapeutics to Present at the SITC 2026 Annual Meeting
Candel Therapeutics announced that it will present data from its aglatimagene besadenovec program in non-small cell lung cancer and clinical findings from its phase 1b trial of linoserpaturev in recurrent glioblastoma at the Society for Immunotherapy of Cancer's 41st Annual Meeting in November 2026. The presentations will showcase multi-omics analyses revealing immune activation and improved survival outcomes.